Table 3 Disease activity and function before and after weight loss treatment in 41 patients with PsA

Weight, kg

106.3 (95.8–113.6)

84–124

82.9 (76.4–92.1)

61.3–107.4

BMI, kg/m²

35.2 (34.1–38.1)

33.0–45.8

29.8 (26.6–31.5)

23.1–37.0

Waist circumference, cm

116 (112–122)

103–135

95.5 (89–103)

81–116

CRP, mg/L

4 (2–8.5)

1–50

2 (1–6.5)

1–50

Hemoglobin, g/L

144 (132–150)

116–179

141 (131.5–148)

118–161

WBC, 10⁹/L

5.9 (5.2–7.6)

4.3–15.2

5.9 (5.0–6.8)

(3.2–12.7)

PLT, 10⁹/L

270 (204–300)

174–444

230 (186–290)

156–402

Tender joints 68, score

4 (1–14)

0–30

2 (0–6.5)

0–19

Swollen joints 66, score

0 (0–1)

0–5

0 (0–0.5)

0–7

VAS patients global disease activity, mm

34 (19–61)

0–93

12 (5–51)

0–95

VAS pain, mm

30 (18.5–62.5)

0–95

20 (5–51.5)

0–95

VAS fatigue, mm

56 (21.5–67)

0–94

25 (8–44)

0–98

DAS28CRP, score

2.9 (2.1–3.7)

1.4–5.6

2.4 (1.7–3.0)

1.2–4.5

DAPSA, score

15.3 (6.6–29.1)

0.9–46

11.0 (2.8–17.6)

0.2–35

Leeds enthesitis index

1 (0–4)

0–6

0 (0–3)

0–4

BSA, %

1.6 (0–2.2)

0–10

0.9 (0–1.1)

0–5.5

HAQ, score

0.70 (0.13–1.00)

0–2.63

0.43 (0–0.69)

0–1.88

DLQI, score

1 (0–4.5)

0–17

1 (0–4)

0–20